Výsledky vyhledávání - "Kiyoshi Hashigami"

Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A Protocol

Autor: Hirotaka Watada, Naoto Katakami, Mitsuyoshi Takahara, Kiyoshi Hashigami, Masaru Kawashima, Iichiro Shimomura, Tomoya Mita

Publikováno v: Diabetes Therapy

Introduction It is estimated that 642 million adults worldwide will have diabetes by 2040, with 80–90% of these having type 2 diabetes mellitus (T2DM). While many new antidiabetic agents have been introduced in recent years, approximately 40% of T2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0745c629d70866007540e20b7e01b9ea
http://europepmc.org/articles/PMC5801237

Zobrazit plný text záznamu

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: R etrospective data for 10 256 individuals from the U nited K ingdom and G ermany

Autor: Marília B. Gomes, Linong Ji, Jesús Medina, Kamlesh Khunti, Laura Garcia‐Alvarez, Antonio Nicolucci, Josh Hiller, Peter Fenici, Stuart J. Pocock, Javier Cid-Ruzafa, Marina Vladimirovna Shestakova, Niklas Hammar, Kiyoshi Hashigami, Mikhail Kosiborod, Thomas Godec, Bernard Charbonnel

Publikováno v: Diabetes, Obesity and Metabolism. 20:389-399

Aim To investigate determinants of change in glycated haemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM) at 6 months after initiating uninterrupted second-line glucose-lowering therapies. Materials and Methods This cohort study util

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ecb40349423fb1e9d475cd3c90a7e669
https://doi.org/10.1111/dom.13083

Zobrazit plný text záznamu

Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program

Autor: Antonio Nicolucci, Stuart J. Pocock, Kiyoshi Hashigami, Linong Ji, Marília B. Gomes, Mikhail Kosiborod, Greg Macaraeg, Peter Fenici, Hirotaka Watada, Jesús Medina, Fabrice Bonnet, Kamlesh Khunti, Wolfgang Rathmann, Bernard Charbonnel, Marina Vladimirovna Shestakova, Iichiro Shimomura, Filip Surmont, Niklas Hammar

Publikováno v: Journal of diabetes and its complications, 31(7):1188-1196

Aim Contemporary global real-world data on the management of type 2 diabetes are scarce. The global DISCOVER study program aims to describe the disease management patterns and a broad range of associated outcomes in patients with type 2 diabetes init

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6db854a0d1cf5cc1149f1bf3594bb98
https://pubmed.ncbi.nlm.nih.gov/28499961

Zobrazit plný text záznamu

Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study

Autor: Shunji Takahashi, Yusuke Onozawa, Nobuko Takenaka, Mitsukuni Suenaga, Kiyohiko Hatake, Kentaro Yamazaki, Kiyoshi Hashigami, Yoshinori Ito, Masahiro Yokoyama, Narikazu Boku, Hirotaka Hasegawa, Shuichi Hironaka

Publikováno v: Japanese journal of clinical oncology. 42(4)

Objective: Neratinib (HKI-272), a potent, irreversible, small-molecule, orally administered, pan-ErbB inhibitor that blocks signal transduction via inhibition of three epidermal growth factor receptors [ErbB1, ErbB2 (Her2) and ErbB4], is being develo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9782dfaa67ef0de0e908f62d4b76a9ae
https://pubmed.ncbi.nlm.nih.gov/22371427

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání